CYP2D6*4 allele and breast cancer risk: Is there any association?

Clinical and Translational Oncology

Volumn 14, Issue 2, 2012, Pages 157-159

  Fernández Santander, Ana ^a   Del Saz Sánchez, Miguel ^a   Tejerina Gómez, Armando ^b   Bandrés Moya, Fernando ^b  

^a UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^b Breast Pathology Center   (Spain)

Author keywords

4 allele; Breast cancer; CYP2D6; CYP2D6 cytochrome; Poor metaboliser

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CYP2D6 GENE; ETHNIC GROUP; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; POPULATION GENETICS; SPANISH; BREAST TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; MIDDLE AGED; PAGET NIPPLE DISEASE; PHENOTYPE; POLYMERASE CHAIN REACTION; RISK FACTOR; SPAIN;

CYTOCHROME P450 2D6; DNA;

ADULT; AGED; ALLELES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; DNA; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS; SPAIN;

EID: 84860732771     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0776-4     Document Type: Article

References (23)

1. Han W, Kang D, Park IA et al (2004) Associations between breast cancer susceptibility gene polymorphisms and clinical pathological features. Clin Cancer Res 10:124-139
2. Chacko P, Joseph T, Mathew BS et al (2005) Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. Mut Res 581:153-163 (Pubitemid 40255903)
3. Bonanni B, Macis D, Maisonneuve P et al (2006) Polymorphism in the CYP2D6 tamoxifen-metabolizing gene infl uences clinical effect but not hot fl ashes: data from the Italian Tamoxifen Trial. J Clin Oncol 24:3708-3709 (Pubitemid 46630548)
4. Sistonen J, Fuselli S, Palo JU et al (2009) Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 9:170-179
5. Ingelman-Sundberg M, Sim SC (2010) Intronic polymorphisms of cytochromes P450. Hum Genomics 4:402-405
6. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13 (Pubitemid 40220611)
7. Dunning AM, Healey CS, Pharoah PDP et al (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843-854 (Pubitemid 29508718)
8. Arvanitidis K, Ragia G, Iordanidou M et al (2007) Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 21:419-426 (Pubitemid 47084032)
9. Buzkova H, Pechandova K, Slanar O, Perlik F (2008) Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochem Funct 26:76-81 (Pubitemid 351155271)
10. Sistonen J, Sajantila A, Lao O et al (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17: 93-101
11. Ladona MG, Abildua RE, Ladero JM et al (1996) CYP2D6 genotypes in Spanish women with breast cancer. Cancer Lett 99:23-28 (Pubitemid 26030349)
12. Ayesh R, Idle JR, Ritchie JC et al (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312:169-170 (Pubitemid 14000084)
13. Khedhaier A, Hassen E, Bouaouina N et al (2008) Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, Meh and NAT2) polymorphisms in breast carcinoma. BMC Cancer 8:109
14. Torresan C, Oliveira MMC, Torrezan GT et al (2008) Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes. Clin Exp Med 8:65-71 (Pubitemid 351999724)
15. Li H, Feng L, Yao L et al (2006) The association of CYP2D6*10 polymorphism with breast cancer risk and clinic-pathologic characteristics in Chinese women. Acta Oncol 45:597-601 (Pubitemid 44167212)
16. Lemos MC, Carrilho F, Rodrigues F et al (2007) Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer. Clin Endocrinol (Oxf) 67:180-183 (Pubitemid 47076289)
17. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 8:227-238 (Pubitemid 28282879)
18. Ouerhani S, Marrakchi R, Bouhaha R et al (2008) The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients. Bull Cancer 95:E1-4
19. Luo YP, Chen HC, Khan MA et al (2011) Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol 32:215-222
20. Agundez JA, Ledesma MC, Benitez J et al (1995) CYP2D6 genes and risk of liver cancer. Lancet 345:830-831
21. Yadav SS, Ruwali M, Pant MC et al (2010) Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response. Mutat Res 684:49-55
22. Strange RC, Ellison T, Ichii-Jones F et al (1999) Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 9:269-276 (Pubitemid 29376370)
23. Gomes L, Lemos MC, Paiva I et al (2005) CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors. Acta Med Port 18:339-343